Abstract:Objective: The aim of the study was to investigate the impact of hormone therapy (HT) on the ocular surface and intraocular pressure in postmenopausal women. Methods: This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses Statement. PubMed, EMBASE, Cochrane Library of Systematic Reviews, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure were searched from inception to November 2019 without language restrictions. Only randomized controlled trials that evaluated the impact of HT on the ocular surface and intraocular pressure in postmenopausal women were eligible. The trials had to report at least one of the following outcomes: break-up time, Schirmer test, corneal staining, ocular surface symptom score, and intraocular pressure. Two investigators independently extracted the information, assessed the risk of bias, and evaluated the publication bias. All data were analyzed by Review Manager V.5.3. Sensitivity analysis and subgroup analysis were performed to find the source of heterogeneity and evaluate the different effects among subgroups. Results: Nine randomized controlled trials (N = 612) were included. The HT group showed significant improvements compared with the control group in break-up time (mean difference [MD] = 2.09, 95% confidence interval [CI] 1.00-3.19, P = 0.0002), Schirmer test without anesthesia (MD = 4.17, 95% CI 1.55-6.80, P = 0.002), Schirmer test with anesthesia (MD = 1.44, 95% CI 0.71-2.18, P = 0.0001), and corneal staining scores (standardized mean difference [SMD] = -0.85, 95% CI -1.39 to -0.30, P = 0.002). Moreover, significant beneficial effects were observed on all four symptoms, including dryness (SMD = -1.21, 95% CI -1.99 to -0.44, P = 0.002), foreign body sensation (SMD = -1.02, 95% CI -1.29 to -0.76, P < 0.00001), ocular fatigue (SMD = -1.74, 95% CI -2.12 to -1.36, P < 0.00001), and burning (SMD = -0.53, 95% CI -0.78 to -0.29, P < 0.0001) after HT. Subgroup analysis revealed that, in terms of break-up time, postmenopausal women younger than 55 years achieved more improvements (MD = 0.88, 95% CI 0.16-1.59, P = 0.02) than women older than 55 years old (MD = 2.60, 95% CI -1.34 to 6.55, P = 0.20), and the estrogen subgroup received more benefits (MD = 3.11, 95% CI 0.93-5.30, P = 0.005) than the estrogen plus progestogen subgroup (MD = 0.42, 95% CI -0.02 to 0.85, P = 0.06). Sensitivity analysis and subgroup analysis suggested that the heterogeneity might derive from the methodological quality, the age of participants, and the intervention of the control group. Intraocular pressure (MD = -1.54, 95% CI -3.39 to 0.32, P = 0.10) was not evidently decreased after HT. No more specific adverse events (relative risk = 1.66, 95% CI 0.41-6.77, P = 0.48) were found in the HT group. Conclusions: Our study revealed that HT could improve ocular surface function in postmenopausal women effectively and safely, especially for those who were younger than 55 years, and estrogen only showed more improvements than estrogen plus progestogen. The effectiveness of HT in treating dry eye in postmenopausal women is, however, still a controversial topic. In addition, we did not find HT led to a significant reduction of intraocular pressure.

Clinical Research of Buddleja Officinalis Tea on Moderate to Severe Xerophthalmia of Menopause Female.

Clinical efficiency of buddleja officinalis tea on middle and severe dry eye of menopause female

Buddleja Officinalis Eye Drops Alleviate The Symptoms Of Moderate To Severe Dry Eye

Clinical Research of Spanishneedles Herb on Middle and Severe Xerophthalmia of Menopause Female

Clinical Study on Spanishneedles Leaves in Treatment of Middle and Severe Xerophthalmia of Menopausal Females

First Clinical Exploration of Genistein on Middle and Severe Dry Eye of Menopause Female.

The application of Mulberry eye drops on xerophthalmia in perimenopausal female rabbit model

Clinical Efficiency of Isoflavone on Middle and Severe Dry Eye of Menopause Female

[Effects of extract of Buddleja officinalis eye drops on androgen receptors of lacrimal gland cells of castrated rats with dry eye]

Zhi-Bai-Di-Huang-Wan, A Classic Chinese Medicinal Formula in Relieving Menopausal Symptoms: A Multi-Centre and Controlled Trial from Uk and China

Prevention Efficiency of Spanishneedles Herb Eye Drops on Rabbit Model with Dry Eye Syndrome in Peri-menopause

Effects of mistletoe eye drops in treating xerophthalmia of perimenopausal female rabbits

A classic chinese medicinal formula in relieving menopausal symptoms : a multi-centre and controlled trial from uk and china

Experimental study on efficiency of Spanishneedles Herb eye drops in treating perimenopausal xerophthalmia in rabbits

The effect of chinese medicinal herbs in relieving menopausal symptoms in ovariectomized chinese women.

[Analysis of the effects on menopausal symptoms, quality of Life, and cardiovascular risk factors of five different therapy in women at early stage of menopause]

Effect of Mistletoe Combined with Carboxymethyl Cellulose on Dry Eye in Postmenopausal Women

The clinical research of calf blood extract eye drops on moderate to severe dry eye

Effect of hormone replacement therapy and comprehensive nursing care on xerophthalmia in postmenopausal women

The effect of hormone therapy on the ocular surface and intraocular pressure for postmenopausal women: a systematic review and meta-analysis of randomized controlled trials

Adjustment of Baihe Tiaogeng Anshen Tang for endocrine function of patients with perimenopausal syndrome